Look beyond drug makers to avoid tragedies like meningitis outbreak, expert says

by Elizabeth K. Gardner

(Medical Xpress)—A Purdue University medication safety expert said it is important to look at the larger system surrounding medication use, as well as the facilities where drugs are made to avoid tragedies like the meningitis outbreak that has claimed 15 lives.

"No one condones making a bad product, but we also need to examine the quality assurance process of the larger medication-use system that doesn't catch it," said John B. Hertig, project manager for the Purdue College of Pharmacy's Center for Medication Safety Advancement. "It is a failure of the larger system and practices that allow a harmful product to make it through numerous hands and be administered to a patient. A system-wide view is the most effective in improving overall ."

The broader pharmaceutical system can be thought of as a stack of slices of Swiss cheese, Hertig said. Each step in the system, from manufacture to shipping and receiving to treatment, has holes where a mistake could go undetected. It is only when the holes in each piece line up that a mistake can make it all the way through to a patient, he said.

The recently linked a meningitis outbreak that spans 15 states to possibly tainted that were made in a Massachusetts facility. The on Monday (Oct. 15) reported 212 people have been infected and 14,000 may have received the injections.

The outbreak raises questions about the oversight of such facilities, called compounding pharmacies, which create customized medication solutions for patients for whom manufactured drugs won't work or are not available, Hertig said.

"In the midst of tragedy our emotions run high and we can get caught up in putting all of the blame on an individual," he said. "We certainly shouldn't tolerate gross negligence, but we also need to take a step back and look at the bigger picture. Even after the individuals responsible for a particular incident have been held accountable, unaddressed flaws in the system will continue to produce negative consequences."

Hertig also is concerned that over-regulation of compounding pharmacies could have the unintended consequence of adding significant costs to the facilities, raising the prices of such treatments and shrinking a critical source of pharmaceuticals.

There have been 200 instances of harmful side effects or illnesses caused by treatments involving 71 compounded products reported to the Food and Drug Administration since 1990, Hertig said.

"It is important to note that these cases represent a very small fraction of the total number of compounded medications dispensed, and without these pharmacies many patients would not have access to much-needed therapies," he said. "Greater regulation may be part of the solution, but enacting increasingly complicated legislation could inhibit compounding pharmacies to the detriment of patient care."

add to favorites email to friend print save as pdf

Related Stories

US clinics rush to warn of tainted steroid; 5 dead

Oct 05, 2012

(AP)—Health providers scrambled to notify patients in nearly two dozen U.S. states that the steroid injections they received for back pain may have been contaminated with a deadly fungal meningitis. Five ...

Tainted drug death toll rises to 14 in US

Oct 11, 2012

The death toll from a deadly meningitis outbreak in the United States blamed on a tainted drug rose to 14 Thursday as the number of cases jumped to 172 in 11 states, health officials said.

Recommended for you

Expression of privilege in vaccine refusal

7 hours ago

Not all students returning to school this month will be up to date on their vaccinations. A new study conducted by Jennifer Reich, a researcher at the University of Colorado Denver, shows that the reasons why children may ...

Using computers to design drugs

Aug 22, 2014

Designing a new medicine is an expensive and time consuming business. Typically it takes around $2 billion and ten years for a new drug to move from its initial design in the lab, to the clinic. All the ...

Lilly psoriasis drug fares well in late-stage test

Aug 22, 2014

Drugmaker Eli Lilly and Co. said its potential psoriasis treatment fared better than both a fake drug and a competitor's product during late-stage testing on patients with the most common form of the skin disease.

User comments